Proteome Sciences elevates drug development with launch of commercial single cell proteomics services
SysQuant® SCP is supported by Proteome’s TMTpro™ isobaric labelling reagents and can identify more than 1,000 proteins in each study of 576 single cells which allows researchers to gain insights into the biology and heterogeneity of individual cells. This can be crucial in understanding complex diseases and identifying potential therapeutic targets. This sits in contrast with traditional methods which typically analyse bulk populations of cells, masking the heterogeneity that may exist among individual cells.
Proteome Sciences' single cell proteomics services are expected to significantly improve the performance of drug development across multiple disease areas including cancer, neurodegeneration, respiratory and cardiac health, and metabolic disorders.
The SysQuant® SCP pipeline analyses mass spectrometry data, uncovering subtle changes in individual cells and sub-populations of the same cell type. This data enhances understanding of heterogeneity and disease evolution, leading to new targets for personalised medicine.
View from Vox
While still in its nascent stages, the field of single cell proteomics is expected to grow rapidly as drug developers look to integrate single cell genomic data with knowledge of protein changes.
Single cell proteomics has been identified as a game-changer in drug discovery, with Proteome well positioned in this field. By analysing individual cells' protein profiles, it helps pinpoint precise disease-associated proteins and potential drug targets within heterogeneous populations. This technology enhances personalised medicine, streamlines preclinical studies, and increases the likelihood of successful drug development by providing detailed insights into the molecular intricacies of diseases and drug actions.
Proteome Sciences shares climbed 13% on the news.
Follow Proteome Sciences for more News and Updates:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.